NGNE - Neurogene, Inc. Common Stock
| Day | 1m | 10m | 60m | PreMarket | Market | AfterHours | Gap |
|---|---|---|---|---|---|---|---|
| 33.41 0.84 (2.51%) | --- | --- | --- | --- | 0.84 (2.51%) | --- | --- |
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Category:
PHARMACEUTICAL PREPARATIONS
Market Period:
Closed
Earnings & Ratios
- Basic EPS:
- -1.05
- Diluted EPS:
- -1.05
- Basic P/E:
- -32.619
- Diluted P/E:
- -32.619
- RSI(14) 1m:
- 68.52
- VWAP:
- 34.32
- RVol:
- 0.4591
Events
| Period | Kind | Movement | Occurred At |
|---|---|---|---|
| 1m | Price increase 1m | 33.89 +0.48 (+1.44%) | Oct 15 14:24 |
| 1m | Price decrease 1m | 33.27 -0.49 (-1.47%) | Oct 15 13:59 |
| 1m | Price decrease 1m | 33.48 -0.34 (-1.01%) | Oct 15 09:49 |
| 1m | Price increase 1m | 33.82 +0.52 (+1.55%) | Oct 15 09:46 |
| 1m | Price decrease 1m | 34.17 -0.37 (-1.07%) | Oct 15 09:36 |